Nerlynx (Neratinib)

Neratinib irreversibly binds to the intracellular kinase domains of HER1, HER2 and HER4 receptors, blocking autophosphorylation and downstream signaling through the PI3K/AKT and MAPK pathways. This inhibition halts cell proliferation and promotes apoptosis in HER2‑driven tumor cells.

The prescribed dose of Nerlynx is determined by the treating physician based on the patient’s clinical condition, prior therapies and tolerability. The standard tablet strength is 240 mg taken orally once daily, but the exact regimen and any dose adjustments must be set by a qualified healthcare professional.

Neratinib is classified as pregnancy category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and effective contraception is required for women of childbearing potential. Safety during breastfeeding has not been established, so nursing mothers should avoid the medication.

To request Nerlynx, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Neratinib is an irreversible pan‑HER tyrosine kinase inhibitor taken orally, whereas agents such as trastuzumab and pertuzumab are monoclonal antibodies administered intravenously. Neratinib offers a convenient oral option and can be used after trastuzumab, but its safety profile, particularly the risk of diarrhea, differs and requires proactive management.

Nerlynx tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

The tablet is taken orally, preferably on an empty stomach, with a full glass of water once daily. Patients should follow the dosing schedule prescribed by their oncologist and may be advised to start antidiarrheal prophylaxis at treatment initiation.

The most serious adverse events include severe diarrhea leading to dehydration, hepatotoxicity manifested by elevated liver enzymes, and cardiac dysfunction such as reduced left ventricular ejection fraction. Prompt recognition and medical intervention are essential to mitigate these risks.

Nerlynx is contraindicated in patients with known hypersensitivity to neratinib or any tablet excipients, in pregnant women, and in individuals with significant hepatic impairment. Caution is also advised for patients with pre‑existing cardiac conditions or those taking strong CYP3A4 inducers.